ImpediMed (IPD) Trading update summary

Capital raise and funding initiatives

• Raised A$13.2 million via a two-tranche placement at A$0.010 per share, with strong support from institutional investors and directors committing A$0.6 million.

• Share purchase plan (SPP) to raise up to A$2.0 million, with potential for oversubscription up to an additional A$1.0 million.

• Each share in the placement and SPP includes one free attaching option and a follow-on option, both subject to shareholder approval.

• Proceeds will partially prepay the SWK Growth Capital Facility and provide working capital for commercial expansion, especially in the US.

• SPP shortfall commitment secured from an institutional fund for up to A$1.8 million if undersubscribed.

Operational and strategic updates

• Implementing initiatives to achieve A$5.0 million in annualised operating cost reductions, effective by 1 July 2026.

• Pathway to operating cash flow breakeven in FY28, assuming full exercise of options.

• Recent growth in annual recurring revenue to $14.1 million and SOZO® Core Business TCV of $5.4 million.

• Expanded BCRL reimbursement to 328 million US covered lives (94.3% national coverage).

• Initiated Heart Health and Weight Management activities in the US, including initial sales.

Placement and SPP details

• Placement issued at a 28.6% discount to last closing price and 28.8% discount to 15-day VWAP.

• Tranche 1 raises A$3.0 million, Tranche 2 raises A$10.2 million, both subject to shareholder approval.

• SPP allows eligible shareholders to subscribe up to A$100,000 at the lower of A$0.010 or a 2.5% discount to 5-day VWAP.

• All options intended to be quoted, subject to ASX requirements.

• Key dates include SPP opening on 12 May 2026 and EGM on 11 June 2026.